Akademik Veri Yönetim Sistemi
Archives of Basic and Clinical Research, cilt.5, sa.1, ss.185-193, 2023 (Hakemli Dergi)
Objective: The purpose of our research was to investigate the frequency of endocrine disorders like diabetes, high blood pres- sure, obesity, hyperuricemia, insulin resistance, and thyroid dys- function, all of which are thought to be critical in the process of diagnosing and treating patients who have dyslipidemia. Methods: Between December 2010 and May 2012, a total of 200 patients with dyslipidemia and 23 healthy control groups without dyslipidemia who applied to the general internal medi- cine and subspecialty outpatient clinics at the Atatürk University Faculty of Medicine were included in the study. The mean age of the dyslipidemic patients was 49 ± 15 years, and the mean age of the healthy control groups was 32 ± 17 years. Anthropometric measures were obtained, as well as measurements of triglycer- ide levels, total cholesterol levels, low-density lipoprotein cho- lesterol levels, high-density lipoprotein cholesterol levels, free T4 levels, Thyroid-stimulating hormone (TSH), The hemoglobin A1c (HbA1C) levels, serum uric acid levels, fasting insulin levels, fasting blood glucose levels and Hemoglobin A1c (HbA1c) . Results: It was shown that diabetes mellitus is the most common endocrine condition that occurs in conjunction with dyslipidemia, with a prevalence of 52%. While there was a statistically signifi- cant increase in HbA1c, body mass index, and uric acid values of the dyslipidemic group compared to the control group (P < .05), no difference was found between the 2 groups in TSH and homeo- stasis model assessment index-insulin resistance (HOMA-IR) val- ues. Also, 85 of the patients in the dyslipidemic group (42.5%) were found to have systemic hypertension, but only one of the patients in the control group (4.3%) had hypertension (p < .001). Conclusion: The frequency of diabetes, hypertension, obesity, and hyperuricemia in patients with dyslipidemia was signifi- cantly higher than in the control group. Considering these dis- eases when treating dyslipidemia is important for cardiovascular morbidity and mortality.